Wang LL - Search Results

1

Novel selective cannabinoid CB(1) receptor antagonist MJ08 with potent in vivo bioactivity and inverse agonistic effects.

Chen W, Xu C, Liu HY, Long L, Zhang W, Zheng ZB, Xie YD, Wang LL, Li S. Chen W, et al. Among authors: wang ll. Acta Pharmacol Sin. 2011 Sep;32(9):1148-58. doi: 10.1038/aps.2011.80. Epub 2011 Aug 15. Acta Pharmacol Sin. 2011. PMID: 21841814 Free PMC article.

2

C16, a novel advanced glycation endproduct breaker, restores cardiovascular dysfunction in experimental diabetic rats.

Cheng G, Wang LL, Qu WS, Long L, Cui H, Liu HY, Cao YL, Li S. Cheng G, et al. Among authors: wang ll. Acta Pharmacol Sin. 2005 Dec;26(12):1460-6. doi: 10.1111/j.1745-7254.2005.00240.x. Acta Pharmacol Sin. 2005. PMID: 16297344

3

C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism.

Xu C, Wang LL, Liu HY, Zhou XB, Cao YL, Li S. Xu C, et al. Among authors: wang ll. Acta Pharmacol Sin. 2006 Feb;27(2):223-8. doi: 10.1111/j.1745-7254.2006.00263.x. Acta Pharmacol Sin. 2006. PMID: 16412273

4

A Cannabinoid-1 Receptor Antagonist MJ08 with Different Effects in Stomach and Small Intestine.

Yu Y, Chen W, Meng D, Zhou XM, Wang LL, Xu C. Yu Y, et al. Among authors: wang ll. Assay Drug Dev Technol. 2021 Apr;19(3):176-183. doi: 10.1089/adt.2020.1041. Epub 2021 Mar 30. Assay Drug Dev Technol. 2021. PMID: 33784479

5

Effects of a fatty acid synthase inhibitor on adipocyte differentiation of mouse 3T3-L1 cells.

Liu LH, Wang XK, Hu YD, Kang JL, Wang LL, Li S. Liu LH, et al. Among authors: wang ll, wang xk. Acta Pharmacol Sin. 2004 Aug;25(8):1052-7. Acta Pharmacol Sin. 2004. PMID: 15301739 Free article.

6

Antitumor activities of a novel indolin-2-ketone compound, Z24: more potent inhibition on bFGF-induced angiogenesis and bcl-2 over-expressing cancer cells.

Wang LL, Li JJ, Zheng ZB, Liu HY, Du GJ, Li S. Wang LL, et al. Eur J Pharmacol. 2004 Oct 11;502(1-2):1-10. doi: 10.1016/j.ejphar.2004.07.048. Eur J Pharmacol. 2004. PMID: 15464084

7

Peroxisome proliferator-activated receptor delta-agonist, GW501516, ameliorates insulin resistance, improves dyslipidaemia in monosodium L-glutamate metabolic syndrome mice.

Chen W, Wang LL, Liu HY, Long L, Li S. Chen W, et al. Among authors: wang ll. Basic Clin Pharmacol Toxicol. 2008 Sep;103(3):240-6. doi: 10.1111/j.1742-7843.2008.00268.x. Epub 2008 Jul 18. Basic Clin Pharmacol Toxicol. 2008. PMID: 18684227 Free article.

8

P633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice.

Chen W, Zhou XB, Liu HY, Xu C, Wang LL, Li S. Chen W, et al. Among authors: wang ll. Br J Pharmacol. 2009 Jul;157(5):724-35. doi: 10.1111/j.1476-5381.2009.00231.x. Epub 2009 May 5. Br J Pharmacol. 2009. PMID: 19422369 Free PMC article.

9

[Establishment of a diabetic-hypertensive rat model].

Zhang B, Cheng G, Liu HY, Wang LL, Li S. Zhang B, et al. Among authors: wang ll. Yao Xue Xue Bao. 2009 Jun;44(6):575-80. Yao Xue Xue Bao. 2009. PMID: 19806885 Chinese.

10

Combination of fenofibrate and rosiglitazone synergistically ameliorate dyslipidemia and insulin resistance in mice with MSG metabolic syndrome.

Chen W, Zhang LH, Liu HY, Zhou XB, Wang LL. Chen W, et al. Among authors: wang ll. Yao Xue Xue Bao. 2010 Nov;45(11):1459-66. Yao Xue Xue Bao. 2010. PMID: 21355528 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,605 results

Search Page

Filters